Ocular Therapeutix (OCUL) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$65.2 million.
- Ocular Therapeutix's Income from Continuing Operations fell 3313.13% to -$65.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$263.5 million, marking a year-over-year decrease of 5962.16%. This contributed to the annual value of -$263.5 million for FY2025, which is 5962.16% down from last year.
- Latest data reveals that Ocular Therapeutix reported Income from Continuing Operations of -$65.2 million as of Q4 2025, which was down 3313.13% from -$68.0 million recorded in Q3 2025.
- Ocular Therapeutix's Income from Continuing Operations' 5-year high stood at -$19.5 million during Q1 2022, with a 5-year trough of -$68.0 million in Q3 2025.
- For the 5-year period, Ocular Therapeutix's Income from Continuing Operations averaged around -$34.4 million, with its median value being -$22.9 million (2022).
- As far as peak fluctuations go, Ocular Therapeutix's Income from Continuing Operations skyrocketed by 1094.77% in 2022, and later plummeted by 11550.88% in 2024.
- Quarter analysis of 5 years shows Ocular Therapeutix's Income from Continuing Operations stood at -$19.7 million in 2021, then dropped by 5.38% to -$20.8 million in 2022, then decreased by 9.42% to -$22.7 million in 2023, then plummeted by 115.51% to -$49.0 million in 2024, then tumbled by 33.13% to -$65.2 million in 2025.
- Its last three reported values are -$65.2 million in Q4 2025, -$68.0 million for Q3 2025, and -$67.2 million during Q2 2025.